FMP
Dec 31, 2024 8:07 AM - Davit Kirakosyan
Image credit: FMP
Stifel analysts increased their price target for Glaukos Corporation (NYSE:GKOS) to $175 from $153 while maintaining a Buy rating. This reflects strong confidence in the company’s iDose technology, which has exceeded lofty expectations among trained surgeons and demonstrated substantial growth potential.
A recent survey of 26 surgeons trained in iDose usage revealed impressive results, with quarterly volume projections supporting a robust fourth-quarter 2024 sales figure in the mid-teen million-dollar range, indicating a likely beat against Street estimates. Looking ahead to 2025, the survey suggests significant upside, with average expected volumes surpassing initial forecasts. This positions iDose to achieve sales exceeding $150 million, well above the current consensus estimate of $106 million.
Key factors driving this optimism include improved reimbursement processes and growing commercial insurance coverage, which are expected to create a favorable operating environment for surgeons utilizing iDose. Additionally, the qualitative feedback from surveyed doctors highlighted a high Net Promoter Score of 69, underscoring the product’s long-term potential and reinforcing confidence in its role over the next five to ten years.
As Glaukos continues to expand its reach and capitalize on the strong performance of iDose, the analysts mentioned that the company is well-positioned to sustain its upward trajectory, solidifying its leadership in innovative ophthalmic solutions.
Sep 10, 2024 11:33 AM - Parth Sanghvi
When it comes to downloading historical stock data, Yahoo Finance has been a popular choice for many. However, for those looking for more comprehensive, accurate, and flexible options, Financial Modeling Prep (FMP) offers a suite of powerful tools and services that stand out as superior alternatives...
Nov 8, 2024 10:30 AM - Sanzhi Kobzhan
When it comes to investing in stocks, one of the key decisions an investor must make involves determining the intrinsic value of a company's shares. Equity valuation isn't just about numbers, it's an art mixed with science, aiming to predict future performance based on current and historical data. H...
Nov 22, 2024 10:08 AM - Parth Sanghvi
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...